PRODUCTIVIDAD MARGINAL DE LA COBERTURA FORESTAL EN LA

The authors thank the research nurses of the Department of Intensive Care Medicine for drug preparation and help during the endotoxemia experiments and Eugénie Terwindt for help with the flow cytometry analysis.

CHAPTER 3

64

REFERENCES

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical care medicine. 2001;29(7):1303-10.

2. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov. 2003;2(5):391-405.

3. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300(4):413-22.

4. Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Critical care. 2011;15(4):R183. 5. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in

patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594-605.

6. Hotchkiss RS, Opal S. Immunotherapy for sepsis--a new approach against an ancient foe. N Engl J Med. 2010;363(1):87-9.

7. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM, et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun. 2010;78(4):1582-92. 8. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138-

50.

9. Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B, et al. Monocytic HLA- DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Critical care medicine. 2009;37(10):2746-52.

10. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive care medicine. 2006;32(8):1175-83.

11. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nature medicine. 2009;15(5):496-7.

12. Flohe SB, Agrawal H, Flohe S, Rani M, Bangen JM, Schade FU. Diversity of interferon gamma and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis. Mol Med. 2008;14(5-6):247-56.

13. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte- macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med. 2002;166(2):138-43.

14. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive care medicine. 2003;29(4):646-51.

15. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640-8.

REVERSAL OF IMMUNOPARALYSIS IN HUMANS IN VIVO. A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PILOT STUDY

65

3

16. Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte- macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Critical care. 2011;15(1):R58.

17. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nature medicine. 1997;3(6):678-81.

18. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Archives of internal medicine. 1997;157(4):389-93.

19. Dorresteijn MJ, Draisma A, van der Hoeven JG, Pickkers P. Lipopolysaccharide-stimulated whole blood cytokine production does not predict the inflammatory response in human endotoxemia. Innate Immun. 2010;16(4):248-53.

20. Kox M, de Kleijn S, Pompe JC, Ramakers BP, Netea MG, van der Hoeven JG, et al. Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia. Critical care medicine. 2011;39(8):1866-70.

21. Draisma A, Pickkers P, Bouw MP, van der Hoeven JG. Development of endotoxin tolerance in humans in vivo. Critical care medicine. 2009;37(4):1261-7.

22. Draisma A, Dorresteijn M, Pickkers P, van der Hoeven H. The effect of systemic iNOS inhibition during human endotoxemia on the development of tolerance to different TLR-stimuli. Innate Immun. 2008;14(3):153-9.

23. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, et al. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol. 1993;151(3):1637-45.

24. Heagy W, Hansen C, Nieman K, Cohen M, Richardson C, Rodriguez JL, et al. Impaired ex vivo lipopolysaccharide-stimulated whole blood tumor necrosis factor production may identify "septic" intensive care unit patients. Shock. 2000;14(3):271-6; discussion 6-7.

25. Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W, et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock. 2006;25(2):129-34.

26. de Vos AF, Pater JM, van den Pangaart PS, de Kruif MD, van 't Veer C, van der Poll T. In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol. 2009;183(1):533-42.

27. van 't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES, et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol. 2007;179(10):7110-20.

28. Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. Journal of leukocyte biology. 1995;58(4):373-81.

29. Bundschuh DS, Barsig J, Hartung T, Randow F, Docke WD, Volk HD, et al. Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol. 1997;158(6):2862-71.

CHAPTER 3

66

30. Randow F, Docke WD, Bundschuh DS, Hartung T, Wendel A, Volk HD. In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-gamma, IL-12, and granulocyte-macrophage colony- stimulating factor. J Immunol. 1997;158(6):2911-8.

31. Chen J, Ivashkiv LB. IFN-gamma abrogates endotoxin tolerance by facilitating Toll-like receptor- induced chromatin remodeling. Proc Natl Acad Sci U S A. 2010;107(45):19438-43.

32. Weijer S, Lauw FN, Branger J, van den Blink B, van der Poll T. Diminished interferon-gamma production and responsiveness after endotoxin administration to healthy humans. J Infect Dis. 2002;186(12):1748-53.

33. Chomarat P, Rissoan MC, Banchereau J, Miossec P. Interferon gamma inhibits interleukin 10 production by monocytes. The Journal of experimental medicine. 1993;177(2):523-7.

34. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature. 1986;323(6083):86-9. 35. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, et al. IL-6 induces an anti-inflammatory

response in the absence of SOCS3 in macrophages. Nature immunology. 2003;4(6):551-6. 36. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of

the cytokine interleukin-6. Biochimica et biophysica acta. 2011;1813(5):878-88.

37. Kline JN, Fisher PA, Monick MM, Hunninghake GW. Regulation of interleukin-1 receptor antagonist by Th1 and Th2 cytokines. Am J Physiol. 1995;269(1 Pt 1):L92-8.

38. Sone S, Orino E, Mizuno K, Yano S, Nishioka Y, Haku T, et al. Production of IL-1 and its receptor antagonist is regulated differently by IFN-gamma and IL-4 in human monocytes and alveolar macrophages. Eur Respir J. 1994;7(4):657-63.

39. Liu JS, Amaral TD, Brosnan CF, Lee SC. IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J Immunol. 1998;161(4):1989-96.

40. van der Poll T, van Deventer SJ, ten Cate H, Levi M, ten Cate JW. Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. J Infect Dis. 1994;169(3):665- 7.

41. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997;99(12):2930-40.

42. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Critical care medicine. 1996;24(7):1125-8. 43. Pachot A, Monneret G, Brion A, Venet F, Bohe J, Bienvenu J, et al. Messenger RNA expression of

major histocompatibility complex class II genes in whole blood from septic shock patients. Critical care medicine. 2005;33(1):31-8; discussion 236-7.

44. Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med. 2004;169(10):1144-51.

45. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem. 2005;51(12):2341-7.

REVERSAL OF IMMUNOPARALYSIS IN HUMANS IN VIVO. A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PILOT STUDY

67

3

46. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohe J, et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive care medicine. 2010;36(11):1859-66.

47. Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive care medicine. 2003;29(8):1245-52.

48. Hynninen M, Pettila V, Takkunen O, Orko R, Jansson SE, Kuusela P, et al. Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock. 2003;20(1):1-4.

49. Wu JF, Ma J, Chen J, Ou-Yang B, Chen MY, Li LF, et al. Changes of monocyte human leukocyte antigen- DR expression as a reliable predictor of mortality in severe sepsis. Critical care. 2011;15(5):R220. 50. Monneret G, Lepape A, Venet F. A dynamic view of mHLA-DR expression in management of severe

CHAPTER 3

68

SUPPLEMENTARY MATERIAL